Atopic dermatitis patients on Janus kinase inhibitors have increased risk of infection compared to biologics: Study
A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on biologics, the patients with moderate-to-severe atopic dermatitis on Janus kinase inhibitors (JAKi) were more susceptible to infections.
Biologics dupilumab (anti-IL-4/13) and tralokinumab (anti-IL-13) and Janus kinase (JAK) inhibitors abrocitinib (JAK1 selective), baricitinib (JAK1/2 selective), and upadacitinib (JAK1 selective) are the two primary types of new, targeted systemic treatments available for moderate-to-severe AD. These treatments have diverse infection risk profiles because of their different mechanisms of action. Biologics may have a more favorable profile, whereas JAK inhibitors (JAKi) may be more risky due to their wider immunosuppressive effects. By comparing the impact of presently available biologic and JAKi therapies on overall infection risk in AD patients in a daily practice scenario, this research seeks to close this gap.
From October 2017 to July 2024, this prospective, multicenter research assessed treatment-emergent infections in patients (age ≥12 years) taking biologics or JAKi from the BioDay registry. For each therapy, crude incidence rates were computed per 100 patient-years (PY). Using subgroup and sensitivity analyses in bio-/JAKi-naïve patients, hazard ratios (HR) for the rate of infections were estimated using Cox regression for recurrent occurrences, adjusted for possible confounders.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.